viernes, 20 de noviembre de 2026

Exposing hidden immune vulnerabilities in KRAS-mutant non-small cell lung cancer

https://www.news-medical.net/news/20261120/Exposing-hidden-immune-vulnerabilities-in-KRAS-mutant-non-small-cell-lung-cancer.aspx In a series of experiments, researchers have found that an experimental MYC inhibitor drug not only targets lung cancer cells directly but also makes cancer cells easier for the immune system to target and kill. MYC is a protein that is known to malfunction in cancer, allowing cells to grow and divide uncontrollably. However, until recently, researchers have struggled to find a way to target MYC. The experimental drug OMO-103 was designed to inhibit MYC and is already being tested with patients in clinical trials. The new research, to be presented on Friday at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, shows that OMO-103 also seems to enable white blood cells to find and destroy cancer cells.

No hay comentarios:

Publicar un comentario